Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE 23:00:00 18/08/2026 +03			5-day change	1st Jan Change
3.210 ^USD	-0.31%		+0.94%	+16.73%

08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
08-11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	368M	-	BBB	-	-
LONZA GROUP AG	48.84B		AAA
REVOLUTION MEDICINES, INC.	45.44B	-	B	-	-
BEONE MEDICINES AG	41.22B		-
IQVIA HOLDINGS INC.	39.71B		AAA
CELLTRION, INC.	32.6B		A
MEDPACE HOLDINGS, INC.	16.67B		BBB
ASCENDIS PHARMA A/S	16.25B	-	-	-	-
EUROFINS SCIENTIFIC SE	14.08B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.68B		AA
ICON PUBLIC LIMITED COMPANY	13.07B		AAA
PHARMARON BEIJING CO., LTD.	12.37B		AA
BIO-TECHNE CORPORATION	11.28B		AA
ABIVAX	10.57B	-	BBB	-	-
PRAXIS PRECISION MEDICINES, INC.	10.51B	-	B	-	-
PROTAGONIST THERAPEUTICS, INC.	10.26B		BB		-
APOGEE THERAPEUTICS, INC.	10.15B	-	B	-	-
KYMERA THERAPEUTICS, INC.	10.1B	-	BBB	-	-
IONIS PHARMACEUTICALS, INC.	9.74B	-	A	-	-
TEMPUS AI, INC.	9.32B		A		-
Average	18.81B		A
Weighted average by Cap.			A